ArticleCancers2022

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.

Umberto Basso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.